Timing of radiotherapy and immunotherapy for lung cancer brain metastases
Part of Brain & nervous system, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial looks at whether the timing of radiation therapy and immunotherapy (like Keytruda or Opdivo) affects outcomes in patients with non-small cell lung cancer (NSCLC) that has spread to the brain. You would receive both treatments as part of your normal care, and the study will track how you do.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (NSCLC) that has spread to your brain, confirmed by MRI.
- Your doctors plan to treat you with radiation plus an immunotherapy drug (PD-1 or PD-L1 inhibitor).
- If you have certain gene changes (driver mutations), your previous targeted treatment didn't work or you don't have them.
- You are in reasonably good health (ECOG score 0-2) and expected to live at least 3 more months.
- You have not had whole-brain radiation, focused brain radiation, or brain surgery for the brain tumors before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a precise, targeted radiation technique for people with lung cancer that has spread to the brain. It aims to treat these brain tumors effectively while limiting harm to healthy tissue, which may help control the cancer and maintain quality of life.
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
This study tests whether giving radiation therapy (called stereotactic radiotherapy) to the brain before or along with a combination of an experimental drug (ivonescimab) and chemotherapy can help treat non-small cell lung cancer that has spread to the brain. It compares this approach to just receiving the drug and chemotherapy without the brain radiation.
Hear when a new Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.